View Item 

Show simple item record

Prevalence of Comorbidities and Their Influence on Blood Pressure Goal Attainment in Geriatric Patients

dc.contributor.authorBisognano, John D.en_US
dc.contributor.authorTownsend, Kevin A.en_US
dc.contributor.authorSkyles, Amy J.en_US
dc.contributor.authorSamuels, Kiela M.en_US
dc.date.accessioned2010-06-01T19:27:20Z
dc.date.available2010-06-01T19:27:20Z
dc.date.issued2007-01en_US
dc.identifier.citationBisognano, John D . ; Townsend, Kevin A . ; Skyles, Amy J . ; Samuels, Kiela M . (2007). "Prevalence of Comorbidities and Their Influence on Blood Pressure Goal Attainment in Geriatric Patients." The American Journal of Geriatric Cardiology 16(1): 24-29. <http://hdl.handle.net/2027.42/72595>en_US
dc.identifier.issn1076-7460en_US
dc.identifier.issn1751-715Xen_US
dc.identifier.urihttps://hdl.handle.net/2027.42/72595
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17215639&dopt=citationen_US
dc.format.extent586847 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherLe Jacqen_US
dc.publisherBlackwell Publishing Ltden_US
dc.rights2007 Le Jacqen_US
dc.titlePrevalence of Comorbidities and Their Influence on Blood Pressure Goal Attainment in Geriatric Patientsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelGeriatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumthe University of Michigan College of Pharmacy, Ann Arbor, MI;en_US
dc.contributor.affiliationumthe University of Michigan Health System, Ann Arbor, MIen_US
dc.contributor.affiliationotherFrom the Program in Heart Failure and Transplantation, Cardiac Rehabilitation, and Clinical Preventive Cardiology, University of Rochester, Rochester, NY;en_US
dc.contributor.affiliationotherPfizer Inc, New York, NY;en_US
dc.identifier.pmid17215639en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/72595/1/j.1076-7460.2007.05543.x.pdf
dc.identifier.doi10.1111/j.1076-7460.2007.05543.xen_US
dc.identifier.sourceThe American Journal of Geriatric Cardiologyen_US
dc.identifier.citedreference1 The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289: 2560 – 2572.en_US
dc.identifier.citedreferenceBurt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey. 1988–1991. Hypertension. 1995; 25: 305 – 313.en_US
dc.identifier.citedreferenceHajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003; 290: 199 – 206.en_US
dc.identifier.citedreference4 US Census Bureau. The 65 Years and Older Population: 2000. Washington, DC: US Census Bureau; 2001.en_US
dc.identifier.citedreference5 Implications of the systolic hypertension in the elderly program. The Systolic Hypertension in the Elderly Program Cooperative Research Group. Hypertension. 1993; 21: 335 – 343.en_US
dc.identifier.citedreferenceFranklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension. 2001; 37: 869 – 874.en_US
dc.identifier.citedreferenceBurt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the health examination surveys, 1960 to 1991. Hypertension. 1995; 26: 60 – 69.en_US
dc.identifier.citedreference8 National Center for Health Statistics. Health Promotion and Disease Prevention United States, 1990. Hyattsville, MD: Public Health Service; 1993: 33. Dept of Health and Human Services publication 93 – 1513.en_US
dc.identifier.citedreferenceLewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaboration. Lancet. 2002; 360: 1903 – 1913.en_US
dc.identifier.citedreference10 The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published corrections appear in JAMA. 2003;289:178 and JAMA. 2004;291:2196]. JAMA. 2002; 288: 2981 – 2997.en_US
dc.identifier.citedreferenceBlack HR, Elliott WJ, Neaton JN, et al, for the CONVINCE Research Group. Baseline characteristics and early blood pressure control in the CONVINCE Trial. Hypertension. 2001; 37: 12 – 18.en_US
dc.identifier.citedreferenceVasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002; 287: 1003 – 1010.en_US
dc.identifier.citedreferenceNeal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 2000; 356: 1955 – 1964.en_US
dc.identifier.citedreference14 National Kidney Foundation Guideline. K/DOQI clinical practice guidelines for chronic kidney disease. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis. 2002; 39 ( suppl 2 ): S1 – S246.en_US
dc.identifier.citedreferenceBlack HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003; 289: 2073 – 2082.en_US
dc.identifier.citedreferenceYusuf S, Sleight P, Poque J, et al, for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342: 145 – 153.en_US
dc.identifier.citedreferencePitt B, Remme W, Zannad F, et al, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309 – 1321.en_US
dc.identifier.citedreference18 UK Prospective Diabetes Study Group. Efficacy of atenolol and captoril in reducing risk of marcrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998; 317: 713 – 720.en_US
dc.identifier.citedreferenceWright JT Jr, Agodoa L, Contreras G, et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med. 2002; 162: 1636 – 1643.en_US
dc.identifier.citedreferenceDahlÖf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002; 359: 995 – 1003.en_US
dc.identifier.citedreference21 The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997; 157: 2413 – 2446.en_US
dc.identifier.citedreference22 Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42: 1206 – 1252.en_US
dc.identifier.citedreferenceWannemacher AJ, Schepers GP, Townsend KA. Antihypertensive medication compliance in a Veterans Affairs Healthcare System. Ann Pharmacother. 2002; 36: 986 – 991.en_US
dc.identifier.citedreferenceDegli Esposti ED, Sturani A, Di Martino M, et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens. 2002; 16: 439 – 444.en_US
dc.identifier.citedreferenceStaessen JA, Fagard R, Thijs L, et al, on behalf of the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997; 350: 757 – 764.en_US
dc.identifier.citedreferenceLloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA. 2005; 294: 466 – 472.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1076-7460.2007.05543.x.pdf
Size:
573.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.